Accessibility Menu
Acro Biomedical logo

Acro Biomedical(OTC) ACBM

Market Cap$1.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-99%
5 Year-99%
1 Year+3,614%
1 Month+0%
$0.03
+0.00%
+0.00Today
Acro Biomedical last closing stock price
MetricPriceDate
Last closeUSD 0.032026-06-16
Acro Biomedical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.032026-04-20
1 month+0%USD 0.032026-04-20
3 month+0%USD 0.032026-03-17
Year to date+17.12%USD 0.022025-12-29
1 year+3,614.29%USD 0.002024-07-15
3 year-98.7%USD 2.002023-06-13
5 year-98.83%USD 2.232021-06-17
Since inception-98.96%USD 2.502018-04-12

Acro Biomedical Financials at a Glance

Market Cap

$1.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$134.62K

EPS (TTM)

-$0.00

P/E Ratio

-11.82

Dividend

$0.00

Beta (Volatility)

-2.51 (Low)

Price

$0.03

Volume

260

Open

$0.03

Previous Close

$0.03

Daily Range

$0.03 - $0.03

52-Week Range

$0.00 - $0.10

Estimated Earnings Date

Nov 19, 2024

ACBM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Acro Biomedical

Acro Biomedical sells cordyceps powder and cordycepin, both used in traditional Chinese medicine. These products are marketed to supplement distributors, not directly to consumers. Cordyceps is believed to support health, especially for those seeking natural remedies.

What’s in the Box? (Products and Services)

  • Cordyceps-related products: Fungus-based supplements sold in bulk to distributors (100% of revenue in 2022).
  • Cordyceps-related products: Includes cordycepin (an extracted compound), used as an ingredient in health products; cordyceps-related products accounted for 100% of revenue in 2022.
  • Metallothionein MT-3 Elizer: Previously sold supplement, not a current product (0% of recent revenue).
  • Cordyceps-Infused Chicken Feed: Development ended in 2023; no marketable product or revenue.

Growth Spurts and Stumbles (Growth and Expansion)

  • Changed name from Killer Waves Hawaii to Acro Biomedical in January 2017.
  • Entered cordyceps supplement market in 2017, focusing on Hong Kong and Taiwan.
  • Launched research for cordyceps-infused chicken feed in 2021; project ended in 2023.
  • Issued 12,282,000 shares to consultants in 2021 for product development.
  • No new product launches or market entries since 2023.

Why Acro Biomedical Is a Bit Different

The company operates with no full-time employees and outsources all production. It relies on a single executive for all sales and management. Acro Biomedical has no proprietary technology or patents, and all products are sourced from third parties.

Five Things You Need to Know

  • No revenue since December 2022; all sales previously from cordyceps products.
  • Two customers made up 100% of revenue in 2022.
  • Net loss was $42,297 in 2024, down 99.5% from 2023.
  • Cash balance was $476 at December 31, 2024.
  • All funding comes from advances by a minority stockholder and the CEO.

Bottom Line

Acro Biomedical has shifted from active sales to minimal operations, with no revenue since 2022. The company now faces significant financial and operational challenges, relying on related-party funding to continue.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

1

CEO

Yu-Ting Su

Website

www.acrobiomedicalco.com

Headquarters

Fishers, IN 46038, US

ACBM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

34.42%

Return on Capital

N/A

Return on Assets

-3475.83%

Earnings Yield

-8.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

60.04M

Volume

260

Avg. Volume

4.127

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$205.36K

EBITDA

-$205.36K

Operating Cash Flow

-$223.59K

Capital Expenditure

-$3.00

Free Cash Flow

-$223.59K

Cash & ST Invst.

$3.87K

Total Debt

$375.11K

Acro Biomedical Performance Analysis

Acro Biomedical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 658,500-45.0%
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Acro Biomedical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Acro Biomedical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.2684.8%
20232023-12-31USD -0.15-44.5%
20242024-12-31USD -0.00-99.5%
20252025-12-31USD -0.00142.9%
Acro Biomedical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-50.0%
Q32025-09-30-566.7%
Q42025-12-31135.0%
Q12026-03-31-200.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.56MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.56M

N/A

Employees

1

N/A

Net Income

-$43.77K

-324.9%

EBITDA

-$60.27K

-574.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.87K

+1443.0%

Total Debt

$375.11K

+126.1%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$375.11K

+126.1%

Return on Assets

-34.76%

N/A

Return on Invested Capital

48.07%

N/A

Free Cash Flow

-$49.82K

-121.1%

Operating Cash Flow

-$49.82K

-121.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NSPDFNaturally Splendid Enterprises Ltd.
$0.04+0.00%
MLPHMolecular Pharmacology (USA), Ltd.
$0.02+0.00%
BSSPBaseline Productions, Inc.
$0.00+0.00%
HDVYHealth Discovery Corporation
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About ACBM

What is the current price of Acro Biomedical?

Acro Biomedical is trading at $0.03 per share.

What is the 52-week range for Acro Biomedical?

Over the past 52 weeks, Acro Biomedical has traded between $0.00 and $0.10.

How much debt does Acro Biomedical have?

As of the most recent reporting period, Acro Biomedical reported total debt of $375.11K.

How much cash does Acro Biomedical have on hand?

Acro Biomedical reported $3.87K in cash and cash equivalents in its most recent financial results.

What is Acro Biomedical’s dividend yield?

Acro Biomedical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services